- All Journals
- Al-Qadisiyah University
- Basrah University
- Kirkuk University
- Mosul University
- The Iraqi Borad for Medical Specialization
- University of Anbar
- University of Technology
- Al Mustafa University
- Al-Zahraa University for Women
- Alnoor University
- Kunooz University
- Misan University
- Ninevah University
- Tikrit University
- University of Al-Hamdaniya
- University of Kerbala
Hodgkin Lymphoma in the Middle Euphrates Region of Iraq: Demographic and Histopathologic Insights | ||
| Al- Anbar Medical Journal | ||
| Volume 22, Issue 2, April 2026, Pages 88-94 PDF (634.36 K) | ||
| Document Type: Original articles | ||
| DOI: 10.33091/amj.2026.166934.2514 | ||
| Authors | ||
| Jehan M. Al-Musawi* 1; Zainab A. Mohsin1; Rafal R. Al-Khalidi2; Sabreen Q. Ibrahim1 | ||
| 1Department of Medicine/Hemato-Oncology, College of Medicine, University of Kufa, Najaf, Iraq. | ||
| 2Department of Surgery/Radiology, College of Medicine, Jabir Ibn Hayyan Medical University, Najaf, Iraq. | ||
| Abstract | ||
| Background: Hodgkin Lymphoma (HL) is among the top ten cancers affecting children and young adults in Iraq, yet epidemiologic and clinical data remain limited. Objective: To identify the epidemiologic and histopathologic trends of HL patients in the Middle Euphrates region of Iraq. Materials and Methods: Medical information of patients registered at the Middle Euphrates Cancer Centre from January 2020 to December 2024 was retrospectively collected and analysed. Demographic, histopathologic, and clinical staging data were extracted. The data were summarized, and correlations were assessed using 95% confidence interval and a significance level of < 0.05. Results: A total of 293 HL cases were included with a median age of 28 years, and a male-to-female ratio of 1.22:1. Seventy percent of patients were younger than 40 years, with a dominant peak between 10 and 30 years. Nodular sclerosis (NS) and mixed cellularity (MC) were the dominant histologic subtypes (40.27% and 38.91%, respectively). NS subtype was significantly more likely to present in pediatric and younger age groups (P-value < 0.001) and at an earlier stage (P-value = 0.018). Conversely, MC showed a tendency to affect older adults (P-value = 0.014). Paediatric and young age groups had higher odds of presenting at an earlier stage than older adults (OR=3.56, P-value=0.031, 95%CI:1.12-11.36) and (OR=5.35, P-value=0.001, 95%CI:1.92-14.93), respectively. Conclusion: HL mainly affects younger age groups, with NS and MC being the most prevalent subtypes. Younger age and NS subtype are significantly associated with earlier stage at presentation, suggesting the need for more age-specific diagnostic and management strategies in this patient population. | ||
| Keywords | ||
| Hodgkin lymphoma; Histologic subtypes; Stage; Middle Euphrates region | ||
| References | ||
|
[1] A. Satou, T. Takahara, and S. Nakamura, "An update on the pathology and molecular features of Hodgkin lymphoma," Cancers, vol. 14, no. 11, p. 2647, 2022.
[2] J. Ferlay et al., "Cancer statistics for the year 2020: An overview," International journal of cancer, vol. 149, no. 4, pp. 778-789, 2021.
[3] M. L. Moleti, A. M. Testi, S. Al-Hadad, M. F. Al-Jadiry, and R. Foà, "Pediatric Hodgkin Lymphoma in Low-and Middle-Income Countries (LMICs). A Narrative Review," Mediterranean Journal of Hematology and Infectious Diseases, vol. 16, no. 1, p. e2024078, 2024.
[4] J. Chen et al., "Global burden of Hodgkin lymphoma among children and adolescents: a population-based study using GBD 2021," Frontiers in Pediatrics, vol. 13, p. 1629229, 2025.
[5] S. M. Ansell, "Hodgkin lymphoma: 2025 update on diagnosis, risk‐stratification, and management," American journal of hematology, vol. 99, no. 12, pp. 2367-2378, 2024.
[6] R. Alaggio et al., "The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms," Leukemia, vol. 36, no. 7, pp. 1720-1748, 2022.
[7] A. Maggioncalda, N. Malik, P. Shenoy, M. Smith, R. Sinha, and C. R. Flowers, "Clinical, molecular, and environmental risk factors for Hodgkin lymphoma," Advances in Hematology, vol. 2011, no. 1, p. 736261, 2011.
[8] T. Al-Juhaishi and S. Ahmed, "Management of limited-stage Hodgkin lymphoma," Hematology, vol. 2023, no. 1, pp. 500-509, 2023.
[9] A. Mjali, S. K. Abbas, A. F. Alwan, and S. K. Hamzah, "Clinical & Pathological Pattern of Hodgkin Lymphoma in Middle Euphrates Region of Iraq," Kerbala Jorunal of Medicine, vol. 13, no. 2, p2355,2020.
[10] E. National Academies of Sciences and Medicine, Childhood cancer and functional impacts across the care continuum. 2020. doi: 10.17226/25944.
[11] F. Fend, "Classical Hodgkin lymphoma and its differential diagnoses," Diagnostic Histopathology, vol. 21, no. 10, pp. 400-407, 2015.
[12] R. P. Shamoon, M. D. Ali, and N. P. Shabila, "Overview and outcome of Hodgkin’s Lymphoma: Experience of a single developing country’s oncology centre," PloS one, vol. 13, no. 4, p. e0195629, 2018.
[13] M. Alalawi et al., "Clinical features and outcomes of newly diagnosed classical Hodgkin lymphoma patients in Saudi Arabia: a multicenter cohort study," Scientific Reports, vol. 15, no. 1, p. 18308, 2025.
[14] J. Huang et al., "Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: a global data analysis," Journal of hematology & oncology, vol. 15, no. 1, p. 57, 2022.
[15] D. M. Craven et al., "Hodgkin lymphoma treatment patterns and outcome disparities in low-and middle-income countries," Blood Global Hematology, vol. 1, no. 3, p. 100021, 2025.
[16] A. Moscona-Nissan, M. F. Mancilla-Osuna, A. Bardán-Duarte, and M. E. Rendón-Macías, "Classical Hodgkin lymphoma histologic subtypes distribution among geographical regions and correlation with Human Development Index," Health Sciences Review, vol. 9, p. 100117, 2023.
[17] S. S. Abbas and R. H. Ali, "10. HODGKIN DISEASE IN CHILDREN," Iraqi Journal of Medical Sciences, vol. 16, no. 4, p. 424-429, 2018.
[18] R. T. Salvaris, B. M. Allanson, G. Collins, and C. Y. Cheah, "Nodular lymphocyte-predominant Hodgkin lymphoma: advances in disease biology, risk stratification, and treatment," Haematologica, vol. 109, no. 11, p. 3476, 2024.
[19] M. Sharma et al., "Clinical and Epidemiological Profile of Elderly Hodgkin’s Lymphoma in India," Cureus, vol. 14, no. 7, 2022.
[20] M. S. Binkley et al., "International prognostic score for nodular lymphocyte–predominant Hodgkin lymphoma," Journal of Clinical Oncology, vol. 42, no. 19, pp. 2271-2280, 2024.
[21] A. Aslani, S. Morsali, S. E. Mousavi, S. Choupani, Z. Yekta, and S. A. Nejadghaderi, "Adult Hodgkin lymphoma incidence trends in the United States from 2000 to 2020," Scientific Reports, vol. 14, no. 1, p. 20500, 2024.
[22] A. Barrett and G. P. Collins, "Older patients with Hodgkin Lymphoma: Walking the tightrope of efficacy and toxicity," Frontiers in Oncology, vol. 12, p. 1017787, 2023.
[23] A. S. Harahap, S. Charles, M. F. Ham, and M. Ham, "A Decade of Prevalence and Clinicopathological Insights Into Classical Hodgkin Lymphoma: A Study From an Indonesian Tertiary Hospital," Cureus, vol. 16, no. 11, 2024.
[24] S. Çokgezer et al., "Treatment responses, toxicity, and survival in patients with classical hodgkin lymphoma aged≥ 50 years: A Single-Center experience over two decades," Cancer Management and Research, pp. 1911-1921, 2022. doi: 10.2147/CMAR.S363235.
[25] M. S. Abbas et al., "Treatment of forty adult patients with Hodgkin disease; Baghdad teaching hospital experience," Journal of the Faculty of Medicine Baghdad, vol. 57, no. 2, pp. 129-133, 2015.
| ||
|
Statistics Article View: 345 PDF Download: 275 |
||